UB Paderborn / Katalog / Suche / in CDI

A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin® (EU and US) in healthy male subjects

British journal of clinical pharmacology, 2018-10, Vol.84 (10), p.2352-2364

2018

Link zum Volltext

Verfügbarkeit prüfen

XG‐102 administered to healthy male volunteers as a single intravenous infusion: a randomized, double‐blind, placebo‐controlled, dose‐escalating study

Pharmacology research & perspectives, 2014-02, Vol.2 (1), p.e00020-n/a

2014

Link zum Volltext

Verfügbarkeit prüfen

A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim

The AAPS journal, 2018-08, Vol.20 (5), p.91-91, Article 91

2018

Link zum Volltext

Verfügbarkeit prüfen

Optimising the use of exercise for the treatment of fibromyalgia

Atención primaria, 2012-11, Vol.44 (11), p.649-650

López-Lázaro, Luis

2012

Link zum Volltext

Verfügbarkeit prüfen

Human Pharmacokinetics and Safety Profile of Finafloxacin, a New Fluoroquinolone Antibiotic, in Healthy Volunteers

Antimicrobial Agents and Chemotherapy, 2011-09, Vol.55 (9), p.4386-4393

2011

Link zum Volltext

Verfügbarkeit prüfen

Phase I and Pharmacokinetic Study of Aplidine, a New Marine Cyclodepsipeptide in Patients With Advanced Malignancies

Journal of clinical oncology, 2005-11, Vol.23 (31), p.7871-7880

2005

Link zum Volltext

Verfügbarkeit prüfen

Mass balance and metabolism of the antimalarial pyronaridine in healthy volunteers

European journal of drug metabolism and pharmacokinetics, 2015-03, Vol.40 (1), p.75-86

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase I Clinical and Pharmacokinetic Study of Kahalalide F in Patients with Advanced Androgen Refractory Prostate Cancer

Clinical cancer research, 2005-03, Vol.11 (5), p.1854-1862

2005

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetic meta-analysis of trabectedin (ET-743, yondelis®) in cancer patients

Clinical pharmacokinetics, 2007-01, Vol.46 (10), p.867-884

2007

Link zum Volltext

Verfügbarkeit prüfen

A Phase I and Pharmacokinetic Study of Ecteinascidin-743 on a Daily × 5 Schedule in Patients with Solid Malignancies

Clinical cancer research, 2002-01, Vol.8 (1), p.75

2002

Link zum Volltext

Verfügbarkeit prüfen

Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma

Journal of global oncology, 2019-12, Vol.5 (5), p.1-13

2019

Link zum Volltext

Verfügbarkeit prüfen

In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug

Investigational new drugs, 2007-02, Vol.25 (1), p.9-19

2007

Link zum Volltext

Verfügbarkeit prüfen

Hepatobiliary damage and changes in hepatic gene expression caused by the antitumor drug ecteinascidin-743 (ET-743) in the female rat

Cancer research (Chicago, Ill.), 2002-08, Vol.62 (15), p.4256-4262

2002

Link zum Volltext

Verfügbarkeit prüfen

Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity

CPT: pharmacometrics and systems pharmacology, 2023-02, Vol.12 (2), p.154-167

2023

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2020-04, Vol.34 (2), p.183-196

2020

Link zum Volltext

Verfügbarkeit prüfen

Comparative double-blind randomized trial of 2 rituximab products in patients with CD20+ diffuse large B-cell lymphoma (DLBCL)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.7550-7550

2017

Link zum Volltext

Verfügbarkeit prüfen

Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies

The AAPS journal, 2019-07, Vol.21 (5), p.85-85, Article 85

2019

Link zum Volltext

Verfügbarkeit prüfen

Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat

Cancer research (Chicago, Ill.), 2003-09, Vol.63 (18), p.5902-5908

2003

Link zum Volltext

Verfügbarkeit prüfen

Active Eosinophilic Esophagitis Is Associated with Impaired Elimination of Budesonide by Cytochrome P450 3A Enzymes

Digestion, 2013-01, Vol.87 (2), p.110-117

2013

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic interaction between pyronaridine-artesunate and metoprolol

Antimicrobial agents and chemotherapy, 2014-10, Vol.58 (10), p.5900-5908

2014

Link zum Volltext

Verfügbarkeit prüfen

A Phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in Patients with solid malignancies

Clinical cancer research, 2002, Vol.8 (1), p.75-85

2002

Link zum Volltext

Verfügbarkeit prüfen

Drug-Drug Interaction Analysis of Pyronaridine/Artesunate and Ritonavir in Healthy Volunteers

The American journal of tropical medicine and hygiene, 2012-03, Vol.86 (3), p.489-495

2012

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Pharmacokinetics and Pharmacodynamics of Two Anti-CD20 Monoclonal Antibodies (Candidate Biosimilar DRL-Rituximab and Innovator Reference Product Rituximab (Mabthera®) in a Randomised, Multi-Centre, Double-Blind, Parallel Group Study of CHOP with Rituximab Chemotherapy in Patients with CD20-Positive Diffuse Large B-Cell Lymphoma

Blood, 2016-12, Vol.128 (22), p.5391-5391

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors

Molecular cancer therapeutics, 2009-06, Vol.8 (6), p.1430-1437

2009

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity

Cancer chemotherapy and pharmacology, 2002-10, Vol.50 (4), p.309-319

2002

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin® (EU and US) in healthy male subjects

XG‐102 administered to healthy male volunteers as a single intravenous infusion: a randomized, double‐blind, placebo‐controlled, dose‐escalating study

A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim

Optimising the use of exercise for the treatment of fibromyalgia

Human Pharmacokinetics and Safety Profile of Finafloxacin, a New Fluoroquinolone Antibiotic, in Healthy Volunteers

Phase I and Pharmacokinetic Study of Aplidine, a New Marine Cyclodepsipeptide in Patients With Advanced Malignancies

Mass balance and metabolism of the antimalarial pyronaridine in healthy volunteers

Phase I Clinical and Pharmacokinetic Study of Kahalalide F in Patients with Advanced Androgen Refractory Prostate Cancer

Population pharmacokinetic meta-analysis of trabectedin (ET-743, yondelis®) in cancer patients

A Phase I and Pharmacokinetic Study of Ecteinascidin-743 on a Daily × 5 Schedule in Patients with Solid Malignancies

Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma

In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug

Hepatobiliary damage and changes in hepatic gene expression caused by the antitumor drug ecteinascidin-743 (ET-743) in the female rat

Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity

Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study

Comparative double-blind randomized trial of 2 rituximab products in patients with CD20+ diffuse large B-cell lymphoma (DLBCL)

Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies

Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat

Active Eosinophilic Esophagitis Is Associated with Impaired Elimination of Budesonide by Cytochrome P450 3A Enzymes

Pharmacokinetic interaction between pyronaridine-artesunate and metoprolol

A Phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in Patients with solid malignancies

Drug-Drug Interaction Analysis of Pyronaridine/Artesunate and Ritonavir in Healthy Volunteers

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors

Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity

Suchergebnisse filtern